Cempra Company Profile (NASDAQ:CEMP)

About Cempra (NASDAQ:CEMP)

Cempra logoCempra, Inc. is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP). Solithromycin has therapeutic potential and activity to target pathogenic bacteria. It has completed two pivotal Phase III trials for solithromycin to treat CABP, as of December 31, 2016. Its Fusidic acid is an antibiotic and the Company is exploring its use for the long-term oral treatment for refractory bone and joint infections (BJI), including prosthetic joint infections, which are caused by staphylococci, including S. aureus, methicillin-resistant S. aureus, coagulase negative staphylococci and other gram-positive bacteria.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:CEMP
  • CUSIP: 15130J10
  • Web: www.cempra.com
  • Market Cap: $147.02 million
  • Outstanding Shares: 52,507,000
Average Prices:
  • 50 Day Moving Avg: $3.14
  • 200 Day Moving Avg: $3.68
  • 52 Week Range: $2.55 - $24.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.94
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $17.65 million
  • Price / Sales: 8.33
  • Book Value: $2.90 per share
  • Price / Book: 0.97
  • EBITDA: ($90,860,000.00)
  • Net Margins: -560.40%
  • Return on Equity: -53.99%
  • Return on Assets: -42.66%
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 12.05%
  • Quick Ratio: 12.04%
  • Average Volume: 812,695 shs.
  • Beta: 1.12
  • Short Ratio: 8.65

Frequently Asked Questions for Cempra (NASDAQ:CEMP)

What is Cempra's stock symbol?

Cempra trades on the NASDAQ under the ticker symbol "CEMP."

How were Cempra's earnings last quarter?

Cempra, Inc. (NASDAQ:CEMP) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.32) by $0.09. The firm earned $0.86 million during the quarter, compared to the consensus estimate of $3.58 million. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The business's revenue for the quarter was down 74.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.51) EPS. View Cempra's Earnings History.

When will Cempra make its next earnings announcement?

Cempra is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for Cempra.

Where is Cempra's stock going? Where will Cempra's stock price be in 2017?

15 analysts have issued 12 month target prices for Cempra's stock. Their forecasts range from $3.00 to $31.00. On average, they anticipate Cempra's stock price to reach $10.90 in the next year. View Analyst Ratings for Cempra.

What are analysts saying about Cempra stock?

Here are some recent quotes from research analysts about Cempra stock:

  • 1. According to Zacks Investment Research, "Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. " (10/17/2017)
  • 2. Robert W. Baird analysts commented, "Cempra announced this morning that the MAA filed in Europe has been withdrawn. We believe it is likely due to the same safety concerns brought up by the FDA. At this point, the path forward for solithromycin appears to us to be a dead end and any additional expenditures will only diminish the company's otherwise attractive cash position. We reiterate our Underperform rating." (3/28/2017)
  • 3. Stifel Nicolaus analysts commented, "Incremental solithromycin updates provided on management's 4Q16 earnings announcement/call now meaningfully increase the likelihood this asset ' in its current formulation ' is unlikely to represent a source of any future value. In addition to FDA seemingly reiterating its stance on wanting 9,000 patients of additional CABP data to assuage hepatotoxicity concerns, EMA is now requesting additional data and management's commentary would suggest any regulatory path forward here is likely to prove challenging. Solithromycin also failed to achieve non-inferiority within the primary cohort of the P3 SOLITAIRE-U trial (gonorrhea), the NASH study has been suspended, and the COPD study has been closed. We've removed all solithromycin-related value (ex-Japan) from our model and believe any viable commercialization argument for Taksta is likely to hinge on YE17 P2 prosthetic joint infection data. Target decreased to $4 (previously $8)." (3/1/2017)

Are investors shorting Cempra?

Cempra saw a drop in short interest in the month of September. As of September 29th, there was short interest totalling 2,520,168 shares, a drop of 36.9% from the September 15th total of 3,995,869 shares. Based on an average daily trading volume, of 1,080,736 shares, the days-to-cover ratio is presently 2.3 days. Approximately 5.4% of the company's shares are short sold.

Who are some of Cempra's key competitors?

Who are Cempra's key executives?

Cempra's management team includes the folowing people:

  • Garheng Kong M.D. Ph.D., Independent Chairman of the Board
  • David Zaccardelli Pharm.D., Acting Chief Executive Officer, Director
  • Mark W. Hahn, Chief Financial Officer, Executive Vice President
  • John D Bluth, Executive Vice President - Investor Relations and Corporate Communications
  • David William Oldach, Chief Medical Officer
  • Michael R. Dougherty, Independent Director
  • David N. Gill, Independent Director
  • Dov A. Goldstein M.D., Independent Director
  • John H. Johnson, Independent Director
  • Richard S. Kent M.D., Independent Director

How do I buy Cempra stock?

Shares of Cempra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cempra's stock price today?

One share of Cempra stock can currently be purchased for approximately $2.80.

MarketBeat Community Rating for Cempra (NASDAQ CEMP)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  338 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  552
MarketBeat's community ratings are surveys of what our community members think about Cempra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cempra (NASDAQ:CEMP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 10 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 1.93)
Consensus Price Target: $10.90 (289.15% upside)
Consensus Price Target History for Cempra (NASDAQ:CEMP)
Price Target History for Cempra (NASDAQ:CEMP)
Analysts' Ratings History for Cempra (NASDAQ:CEMP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/14/2017Jefferies Group LLCReiterated RatingHold$3.00MediumView Rating Details
8/10/2017Roth CapitalDowngradeBuy -> Neutral$8.00 -> $4.00HighView Rating Details
8/10/2017Stifel NicolausReiterated RatingHold$4.00HighView Rating Details
3/29/2017GabelliDowngradeHold -> SellHighView Rating Details
3/28/2017Robert W. BairdReiterated RatingUnderperformMediumView Rating Details
1/12/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
1/2/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
1/2/2017Cantor FitzgeraldSet Price TargetBuy$28.00N/AView Rating Details
12/30/2016Needham & Company LLCReiterated RatingHoldN/AView Rating Details
12/30/2016Morgan StanleyUpgradeUnderweight -> Equal Weight$5.00 -> $5.00N/AView Rating Details
12/29/2016WBB SecuritiesDowngradeBuy -> Hold$40.00 -> $4.00N/AView Rating Details
12/29/2016S&P Equity ResearchBoost Price Target$2.65 -> $3.15N/AView Rating Details
12/29/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
12/20/2016SunTrust Banks, Inc.DowngradeBuy -> Sell$18.00 -> $5.00N/AView Rating Details
11/8/2016Royal Bank Of CanadaReiterated RatingBuy$27.50N/AView Rating Details
11/2/2016Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformN/AView Rating Details
5/10/2016Janney Montgomery ScottReiterated RatingHoldN/AView Rating Details
5/2/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Cempra (NASDAQ:CEMP)
Earnings by Quarter for Cempra (NASDAQ:CEMP)
Earnings History by Quarter for Cempra (NASDAQ CEMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017($0.17)N/AView Earnings Details
8/9/2017Q2 2017($0.32)($0.23)$3.58 million$0.86 millionViewListenView Earnings Details
4/28/2017Q1 2017($0.53)($0.37)$3.55 million$4.87 millionViewN/AView Earnings Details
2/28/2017Q4 2016($0.57)($0.60)$4.19 million$7.95 millionViewListenView Earnings Details
10/27/2016Q3($0.64)($0.62)$3.90 million$4.00 millionViewListenView Earnings Details
8/1/2016Q2($0.67)($0.51)$3.89 million$3.42 millionViewN/AView Earnings Details
5/1/2016Q1($0.63)($0.61)$3.94 million$2.70 millionViewN/AView Earnings Details
2/24/2016Q4($0.59)($0.48)$3.89 million$5.79 millionViewListenView Earnings Details
10/22/2015Q315($0.52)($0.63)$4.70 million$2.50 millionViewListenView Earnings Details
7/29/2015Q2($0.41)($0.57)$4.60 million$5.05 millionViewListenView Earnings Details
4/30/2015Q1($0.43)($0.41)$2.90 million$13.96 millionViewListenView Earnings Details
2/25/2015Q414($0.46)($0.46)$3.50 million$2.47 millionViewListenView Earnings Details
10/29/2014Q314($0.59)($0.34)$1.59 million$7.77 millionViewN/AView Earnings Details
7/29/2014Q214($0.56)($0.49)$2.56 million$1.90 millionViewN/AView Earnings Details
4/29/2014Q114($0.48)($0.51)$2.10 million$3.10 millionViewN/AView Earnings Details
2/27/2014Q413($0.42)($0.51)$1.25 million$2.07 millionViewN/AView Earnings Details
10/29/2013Q313($0.29)($0.41)$0.46 million$1.20 millionViewN/AView Earnings Details
7/30/2013Q3 2013($0.42)($0.16)$5.13 million$4.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cempra (NASDAQ:CEMP)
2017 EPS Consensus Estimate: ($1.22)
2018 EPS Consensus Estimate: ($0.77)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.55)($0.48)($0.51)
Q2 20173($0.39)($0.26)($0.32)
Q3 20173($0.24)($0.18)($0.21)
Q4 20173($0.20)($0.16)($0.18)
Q1 20181($0.19)($0.19)($0.19)
Q2 20181($0.20)($0.20)($0.20)
Q3 20181($0.20)($0.20)($0.20)
Q4 20181($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)


Dividend History for Cempra (NASDAQ:CEMP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cempra (NASDAQ:CEMP)
Insider Ownership Percentage: 17.80%
Institutional Ownership Percentage: 49.75%
Insider Trades by Quarter for Cempra (NASDAQ:CEMP)
Institutional Ownership by Quarter for Cempra (NASDAQ:CEMP)
Insider Trades by Quarter for Cempra (NASDAQ:CEMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/8/2017Dov A Md GoldsteinDirectorSell150,000$3.55$532,500.00View SEC Filing  
1/13/2017Dov A Md GoldsteinDirectorSell105,460$3.40$358,564.00View SEC Filing  
1/6/2017Dov A Md GoldsteinDirectorSell937,600$3.41$3,197,216.00View SEC Filing  
1/3/2017David N GillDirectorBuy5,000$2.94$14,700.00View SEC Filing  
3/1/2016David MooreInsiderBuy500$16.18$8,090.00View SEC Filing  
1/4/2016Dov A. Md GoldsteinDirectorSell842$30.06$25,310.52View SEC Filing  
12/15/2015David W. OldachinsiderSell10,000$30.27$302,700.00View SEC Filing  
11/9/2015David W. OldachinsiderSell12,200$28.78$351,116.00View SEC Filing  
10/26/2015Garheng KongDirectorBuy2,830$17.43$49,326.90View SEC Filing  
6/22/2015Dov A Md GoldsteinDirectorSell50,000$35.74$1,787,000.00View SEC Filing  
5/23/2014John JohnsonDirectorBuy10,000$9.10$91,000.00View SEC Filing  
6/19/2013P Sherrill NeffDirectorBuy265,000$7.00$1,855,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cempra (NASDAQ:CEMP)
Latest Headlines for Cempra (NASDAQ:CEMP)
americanbankingnews.com logoCempra, Inc. (CEMP) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - October 18 at 5:38 AM
americanbankingnews.com logoZacks Investment Research Upgrades Cempra, Inc. (CEMP) to "Hold"
www.americanbankingnews.com - October 17 at 10:26 PM
americanbankingnews.com logoCempra, Inc. (CEMP) Sees Significant Decline in Short Interest
www.americanbankingnews.com - October 14 at 2:04 AM
thestreet.com logoShort Interest In Cempra Decreases By 37%
www.thestreet.com - October 11 at 6:37 PM
americanbankingnews.com logoCempra, Inc. (CEMP) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 11 at 2:32 AM
finance.yahoo.com logoMelinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne
finance.yahoo.com - October 10 at 6:16 PM
finance.yahoo.com logoETFs with exposure to Cempra, Inc. : October 9, 2017
finance.yahoo.com - October 9 at 5:46 PM
americanbankingnews.com logoCempra, Inc. (CEMP) Expected to Announce Quarterly Sales of $2.99 Million
www.americanbankingnews.com - October 9 at 3:30 AM
finance.yahoo.com logoAntimicrobials Working Group Highlights Member Company Participation at IDWeek 2017
finance.yahoo.com - October 5 at 11:39 AM
reuters.com logoBRIEF-Cempra and Melinta announce expiration of Hart-Scott-Rodino waiting period for proposed merger
www.reuters.com - September 28 at 5:06 PM
finance.yahoo.com logoMelinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma Laboratórios
finance.yahoo.com - September 26 at 8:38 AM
thestreet.com logoAmarin And HLS Therapeutics Announce Agreement To Commercialize Vascepa® In Canada
www.thestreet.com - September 25 at 7:44 PM
finance.yahoo.com logoMelinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other Infections
finance.yahoo.com - September 25 at 7:44 PM
americanbankingnews.com logo Brokerages Expect Cempra, Inc. (CEMP) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - September 19 at 12:26 AM
americanbankingnews.com logoCempra, Inc. (CEMP) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 2:46 AM
americanbankingnews.com logoCempra, Inc. (CEMP) Given Hold Rating at Jefferies Group LLC
www.americanbankingnews.com - September 14 at 7:16 PM
seekingalpha.com logoCEMPRA (CEMP) Presents At Morgan Stanley 15th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - September 13 at 11:18 PM
prnewswire.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Cempra, Inc. -- CEMP - PR Newswire (press release)
www.prnewswire.com - September 11 at 5:44 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Cempra, Inc. -- CEMP
finance.yahoo.com - September 10 at 4:35 PM
globenewswire.com logoCempra Announces Presentations at Upcoming Investor Conferences and Provides Merger Process Update - GlobeNewswire (press release)
globenewswire.com - September 9 at 4:46 PM
finance.yahoo.com logoCempra Announces Presentations at Upcoming Investor Conferences and Provides Merger Process Update
finance.yahoo.com - September 7 at 5:12 PM
finance.yahoo.com logoETFs with exposure to Cempra, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 9:59 PM
finance.yahoo.com logoCempra, Inc. :CEMP-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 25 at 6:51 PM
americanbankingnews.com logoCempra, Inc. (CEMP) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - August 22 at 2:32 AM
seekingalpha.com logoSome Early Observations On The Cempra Merger With Melinta - Seeking Alpha
seekingalpha.com - August 14 at 5:27 PM
americanbankingnews.com logoResearch Analysts Issue Forecasts for Cempra, Inc.'s FY2018 Earnings (CEMP)
www.americanbankingnews.com - August 14 at 8:52 AM
americanbankingnews.com logoCempra, Inc. to Post Q3 2017 Earnings of ($0.21) Per Share, Jefferies Group Forecasts (NASDAQ:CEMP)
www.americanbankingnews.com - August 14 at 3:34 AM
americanbankingnews.com logoCempra, Inc. (CEMP) Expected to Post Quarterly Sales of $3.25 Million
www.americanbankingnews.com - August 14 at 1:16 AM
streetinsider.com logoForm DEFA14A CEMPRA, INC. - StreetInsider.com
www.streetinsider.com - August 12 at 9:41 PM
seekingalpha.com logoCempra And Melinta's Lesson In Value Destruction - Seeking Alpha
seekingalpha.com - August 12 at 9:41 PM
finance.yahoo.com logo[$$] Melinta to Secure Public Listing With Cempra Merger
finance.yahoo.com - August 11 at 5:29 PM
streetinsider.com logoForm DEFA14A CEMPRA, INC.
www.streetinsider.com - August 10 at 6:15 PM
reuters.com logoBRIEF-Cempra Inc - merger ‍agreement with Melinta provides for payment of termination fee of $7.9 mln by each co
www.reuters.com - August 10 at 6:15 PM
News IconBRIEF-Cempra reports Q2 loss per share $0.23
www.businessinsider.com - August 10 at 3:19 AM
seekingalpha.com logoCempra, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 10 at 3:19 AM
finance.yahoo.com logoEdited Transcript of CEMP earnings conference call or presentation 9-Aug-17 12:45pm GMT
finance.yahoo.com - August 10 at 3:19 AM
americanbankingnews.com logoCempra, Inc. (CEMP) Releases Earnings Results, Beats Expectations By $0.09 EPS
www.americanbankingnews.com - August 9 at 5:32 PM
globenewswire.com logoCempra and Melinta Announce Merger to Form Leading, Vertically Integrated Commercial-Stage Anti-Infectives ... - GlobeNewswire (press release)
globenewswire.com - August 9 at 5:16 PM
finance.yahoo.com logoInvestor Network: Cempra, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 5:16 PM
finance.yahoo.com logoCempra and Melinta Announce Merger to Form Leading, Vertically Integrated Commercial-Stage Anti-Infectives Company
finance.yahoo.com - August 9 at 5:16 PM
finance.yahoo.com logoCempra Provides Corporate Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 5:16 PM
finance.yahoo.com logoMalin Investee Company - Melinta Therapeutics - To Be Transformed into a NASDAQ Listed Company
finance.yahoo.com - August 9 at 5:16 PM
finance.yahoo.com logoCempra joins with Melinta to form new company that intends to go public
finance.yahoo.com - August 9 at 5:16 PM
finance.yahoo.com logoThese Two Biotech Stocks Are Going Berserk on Wednesday
finance.yahoo.com - August 9 at 5:16 PM
finance.yahoo.com logoCempra reports 2Q loss
finance.yahoo.com - August 9 at 5:15 PM
americanbankingnews.com logoHead-To-Head Review: Cempra (CEMP) versus Auspex Pharmaceuticals (ASPX)
www.americanbankingnews.com - July 29 at 7:26 AM
americanbankingnews.com logoCempra, Inc. (NASDAQ:CEMP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 10:03 AM
americanbankingnews.com logo Analysts Anticipate Cempra, Inc. (NASDAQ:CEMP) Will Announce Quarterly Sales of $3.43 Million
www.americanbankingnews.com - July 27 at 11:22 AM
americanbankingnews.com logo Analysts Expect Cempra, Inc. (CEMP) to Post -$0.32 Earnings Per Share
www.americanbankingnews.com - July 25 at 8:18 PM
americanbankingnews.com logoCempra, Inc. (CEMP) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - July 24 at 8:18 AM



Cempra (CEMP) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.